Investors
Why Invest in
IpiNovyx Bio?
IpiNovyx Bio is at the forefront of developing innovative therapies for cancer, autoimmune and inflammatory diseases, leveraging our proprietary proteasome modulation platform. With strong backing from leading investors like Eli Lilly and Company and strategic collaborations with top academic institutions, we are uniquely positioned to transform patient care in areas with significant unmet medical needs. As we advance our pipeline toward clinical trials, we offer a compelling opportunity for investors looking to support groundbreaking advancements in biopharmaceuticals.
Investment Highlights
Pioneering Technology: Our proprietary platform enables the creation of highly selective and reversible immunoproteasome inhibitors, offering a novel approach to treating complex diseases.
Strong Partnerships: Collaborations with prestigious institutions such as Weill Cornell Medicine and the Hospital for Special Surgery enhance our research capabilities and innovation.
Robust Pipeline: We are advancing a portfolio of drug candidates designed to address significant unmet medical needs, with clinical trials anticipated by mid-2026.
Experienced Leadership: Our team brings together decades of experience in biopharmaceutical research, development, and commercialization.
Recent News
Read about our latest developments, including funding rounds, partnership announcements, and progress in our pipeline.
